192718-06-2
192718-06-2 結構式
基本信息
C527 >=98% (HPLC)
2-(4-Fluorophenyl)-naphth[2,3-d]oxazole-4,9-dione
2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione
Naphth[2,3-d]oxazole-4,9-dione, 2-(4-fluorophenyl)-
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-12988 | C527 | 192718-06-2 | 1 mg | 120元 |
| 2026/06/05 | HY-12988 | 192718-06-2 C527 | 192718-06-2 | 5mg | 300元 |
| 2026/06/05 | HY-12988 | 192718-06-2 C527 | 192718-06-2 | 10mg | 500元 |
常見問題列表
0.88 μM (USP1)
Pretreatment of USP1/UAF1 with C527 resulted in inhibition of its enzyme activity with an IC 50 of 0.88±0.03 μM. C527 inhibits the DUB activity of the USP12/USP46 complex and other DUB enzymes in vitro . However, the IC 50 of C527 for these DUB enzymes was higher in comparison with USP1/UAF1 complex. C527 has considerably less inhibitory effect on UCH-L1 and UCH-L3, a different subclass of DUB enzymes. C527 treatments causes an increase in the levels of Ub-FANCD2 and Ub-FANCI. Pretreatment of cells with the C527 causes an enhancement in the cytoxicity of mitomycin C and camptothecin. C527 treatments lead to an increase in ubiquitinated forms of FANCD2 and FANCI, cause a decrease in homologous recombination activity, and sensitize cells to DNA damaging agents.